Biomedical Engineering Reference
In-Depth Information
cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in
infected human macrophages. Antivir Ther 9:519-528.
134. Kim RB. 2003. Drug transporters in HIV therapy. Top HIV Med 11:136-139.
135. Quirk E, McLeod H, Powderly W. 2004. The pharmacogenetics of antiretroviral therapy:
a review of studies to date. Clin Infect Dis 39:98-106.
136. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer
H, Opravil M, Pantaleo G, et al. 2002. Response to antiretroviral treatment in HIV-
1-infected individuals with allelic variants of the multidrug resistance transporter 1: a
pharmacogenetics study. Lancet 359:30-36.
137. Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR,
Clifford DB, D'Aquila RT, De Gruttola V, et al. 2005. Pharmacogenetics of long-term
responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult AIDS
Clinical Trials Group study. J Infect Dis 192:1931-1942.
138. Colombo S, Soranzo N, Rotger M, Sprenger R, Bleiber G, Furrer H, Buclin T, Goldstein
D, Decosterd L, Telenti A. 2005. Influence of ABCB1, ABCC1, ABCC2, and ABCG2
haplotypes on the cellular exposure of nelfinavir in vivo. Pharmacogenet Genom 15:599-
608.
139. Haas DW, Wu H, Li H, Bosch RJ, Lederman MM, Kuritzkes D, Landay A, Connick E,
Benson C, Wilkinson GR, Kessler H, Kim RB. 2003. MDR1 gene polymorphisms and
phase 1 viral decay during HIV-1 infection: an Adult AIDS Clinical Trials Group study.
J Acquir Immune Defic Syndr 34:295-298.
140. Nasi M, Borghi V, Pinti M, Bellodi C, Lugli E, Maffei S, Troiano L, Richeldi L, Mussini
C, Esposito R, Cossarizza A. 2003. MDR1 C3435T genetic polymorphism does not
influence the response to antiretroviral therapy in drug-naive HIV-positive patients. AIDS
17:1696-1698.
141. Brumme ZL, Dong WW, Chan KJ, Hogg RS, Montaner JS, O'Shaughnessy MV, Harrigan
PR. 2003. Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial
antiretroviral therapy response. AIDS 17:201-208.
142. Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, Raffel C. 1995. MDR1
gene expression in brain of patients with medically intractable epilepsy. Epilepsia 36:
1-6.
143. Potschka H, Fedrowitz M, Loscher W. 2001. P-Glycoprotein and multidrug resistance-
associated protein are involved in the regulation of extracellular levels of the major
antiepileptic drug carbamazepine in the brain. Neuroreport 12:3557-3560.
144. Potschka H, Loscher W. 2001. In vivo evidence for P-glycoprotein-mediated transport of
phenytoin at the blood-brain barrier of rats. Epilepsia 42:1231-1240.
145. Maines LW, Antonetti DA, Wolpert EB, Smith CD. 2005. Evaluation of the role of P-
glycoprotein in the uptake of paroxetine, clozapine, phenytoin and carbamazapine by
bovine retinal endothelial cells. Neuropharmacology 49:610-617.
146. Owen A, Pirmohamed M, Tettey JN, Morgan P, Chadwick D, Park BK. 2001. Carba-
mazepine is not a substrate for P-glycoprotein. Br J Clin Pharmacol 51:345-349.
147. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, Wood NW,
Sisodiya SM. 2003. Association of multidrug resistance in epilepsy with a polymorphism
in the drug-transporter gene ABCB1. N Engl J Med 348:1442-1448.
148. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa
J, Higuchi S, Terakawa N, Otsubo K. 2001. Expression of P-glycoprotein in human
Search WWH ::
Custom Search